BLTE net incomeFY2025-$77.61M
BLTE net income was -$77.61M for fiscal 2025 (ended Dec 31, 2025), compared with -$36.14M in fiscal 2024.
Belite Bio Inc (BLTE) financials
For fiscal 2025 (ended Dec 31, 2025), Belite Bio Inc reported -$77.61M of net income.
- Net income, FY2025
- -$77.61M
- Free cash flow, FY2025
- -$37.06M
- EPS, diluted, FY2025
- -$2.31
- Cash
- $352.93M
- Market cap
- $6.35B
FY2020FY2025
FY2021FY2025
BLTE revenue and earnings growth
BLTE EPSFY2025-$2.31
BLTE diluted EPS was -$2.31 for fiscal 2025 (ended Dec 31, 2025), compared with -$1.18 in fiscal 2024.
BLTE free cash flowFY2025-$37.06M
BLTE free cash flow was -$37.06M for fiscal 2025 (ended Dec 31, 2025), compared with -$29.35M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $45.38M | $29.94M | $24.84M | $8.87M | $7.42M | $3.69M |
| Selling, general and admin | $38.83M | $10.06M | $6.82M | $3.95M | $2.38M | $2.06M |
| Operating income | -$84.21M | -$40.00M | -$31.67M | -$12.82M | -$9.80M | -$5.74M |
| Interest expense | $2.0K | $20.0K | $25.0K | $16.0K | - | $21.0K |
| Pre-tax income | -$77.61M | -$36.14M | -$31.62M | -$12.65M | -$9.67M | -$5.75M |
| Income tax | $0 | $6.0K | $9.0K | - | - | $1.0K |
| Net income | -$77.61M | -$36.14M | -$31.63M | -$12.65M | -$9.67M | -$5.75M |
| EPS, basic | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
| EPS, diluted | -$2.31 | -$1.18 | -$1.19 | -$0.63 | -$1.01 | -$0.65 |
| Diluted shares | 33.5M | 30.5M | 26.6M | 20.0M | 9.6M | 8.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $352.93M | $31.68M | $88.16M | $42.09M | $17.34M | $25.62M |
| Current assets | $494.27M | $147.07M | $89.94M | $42.81M | $17.43M | - |
| Total assets | $780.56M | $152.13M | $94.64M | $44.27M | $18.35M | - |
| Current liabilities | $9.88M | $6.05M | $3.63M | $2.10M | $1.64M | - |
| Total liabilities | $10.07M | $6.31M | $4.21M | $2.77M | $1.64M | - |
| Shareholders' equity | $770.49M | $145.82M | $90.43M | $41.50M | -$15.09M | -$7.04M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$36.99M | -$29.23M | -$29.84M | -$11.46M | -$7.47M | -$4.44M |
| Capital expenditures | $71.0K | $116.0K | $63.0K | $394.0K | $74.0K | - |
| Free cash flow | -$37.06M | -$29.35M | -$29.90M | -$11.85M | -$7.55M | - |
| Investing cash flow | -$305.11M | -$110.57M | -$63.0K | -$394.0K | -$56.0K | -$20.0K |
| Financing cash flow | $663.23M | $83.59M | $75.96M | $36.96M | -$583.0K | $28.06M |
| Stock-based compensation | $38.92M | $8.99M | $3.82M | $1.48M | $1.53M | $1.36M |
Key ratios
Source: XBRL data Belite Bio Inc files with the SEC, latest filing dated Mar 31, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BLTE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BLTE | - | - | -$77.61M | - | $6.35B |
| OCGN | $4.41M | +8.8% | -$67.85M | -1537.4% | $327.4M |
| ANNX | - | - | -$198.96M | - | $801.9M |
| IONS | $960.09M | -0.7% | -$546.54M | -56.9% | $5.15B |
BLTE FAQ
6 questionsIs BLTE profitable?
No. Belite Bio Inc reported a net loss of $77.61M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BLTE have?
Belite Bio Inc reported $352.93M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is BLTE free cash flow?
Belite Bio Inc generated -$37.06M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$36.99M less capital expenditures.What is BLTE earnings per share?
Diluted earnings per share were -$2.31 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did BLTE last report financial results?
The latest statements here come from Belite Bio Inc's 20-F filed on Mar 31, 2026, covering the period ended Dec 31, 2025.Where does this BLTE financial data come from?
Quantisnow builds these statements from the structured XBRL data Belite Bio Inc files with the SEC. It is provided for information only and is not investment advice.